BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 16230048)

  • 1. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.
    Roth T; Walsh JK; Krystal A; Wessel T; Roehrs TA
    Sleep Med; 2005 Nov; 6(6):487-95. PubMed ID: 16230048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polysomnography study of eszopiclone in elderly patients with insomnia.
    McCall WV; Erman M; Krystal AD; Rosenberg R; Scharf M; Zammit GK; Wessel T
    Curr Med Res Opin; 2006 Sep; 22(9):1633-42. PubMed ID: 16968566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone.
    Boyle J; Trick L; Johnsen S; Roach J; Rubens R
    Hum Psychopharmacol; 2008 Jul; 23(5):385-97. PubMed ID: 18350566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia.
    Najib J
    Clin Ther; 2006 Apr; 28(4):491-516. PubMed ID: 16750462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial.
    Soares CN; Joffe H; Rubens R; Caron J; Roth T; Cohen L
    Obstet Gynecol; 2006 Dec; 108(6):1402-10. PubMed ID: 17138773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eszopiclone for insomnia.
    Melton ST; Wood JM; Kirkwood CK
    Ann Pharmacother; 2005 Oct; 39(10):1659-66. PubMed ID: 16131537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults.
    Rosenberg R; Caron J; Roth T; Amato D
    Sleep Med; 2005 Jan; 6(1):15-22. PubMed ID: 15680290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
    Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
    Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A WASO sub-group analysis of a 6-month study of eszopiclone 3 mg.
    Krystal AD; Huang H; Zummo J; Grinnell T; Marshall RD
    Sleep Med; 2012 Jun; 13(6):691-6. PubMed ID: 22465450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia.
    Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T
    Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia.
    Krystal AD; Walsh JK; Laska E; Caron J; Amato DA; Wessel TC; Roth T
    Sleep; 2003 Nov; 26(7):793-9. PubMed ID: 14655910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome.
    Rosenberg R; Roach JM; Scharf M; Amato DA
    Sleep Med; 2007 Aug; 8(5):464-70. PubMed ID: 17512799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.
    Lydiard RB; Lankford DA; Seiden DJ; Landin R; Farber R; Walsh JK
    J Clin Sleep Med; 2006 Jul; 2(3):309-15. PubMed ID: 17561543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study.
    Dorsey CM; Lee KA; Scharf MB
    Clin Ther; 2004 Oct; 26(10):1578-86. PubMed ID: 15598474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia.
    Roth T; Seiden D; Sainati S; Wang-Weigand S; Zhang J; Zee P
    Sleep Med; 2006 Jun; 7(4):312-8. PubMed ID: 16709464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients.
    Walsh JK; Thacker S; Knowles LJ; Tasker T; Hunneyball IM
    Sleep Med; 2009 Sep; 10(8):859-64. PubMed ID: 19345644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial.
    Pollack MH; Hoge EA; Worthington JJ; Moshier SJ; Wechsler RS; Brandes M; Simon NM
    J Clin Psychiatry; 2011 Jul; 72(7):892-7. PubMed ID: 21367352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.